Controlled trial of cyclophosphamide in idiopathic membranous nephropathy
نویسندگان
چکیده
منابع مشابه
Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.
BACKGROUND AND OBJECTIVES Cyclophosphamide treatment improves renal survival in patients with idiopathic membranous nephropathy. However, use of cyclophosphamide is associated with cancer. The incidence of malignancies in patients with idiopathic membranous nephropathy was evaluated, and the cancer risk associated with cyclophosphamide use was estimated. DESIGN, SETTING, PARTICIPANTS, & MEASU...
متن کاملTreatment of idiopathic membranous nephropathy.
Exciting progress recently has been made in our understanding of idiopathic membranous nephropathy, as well as treatment of this disease. Here, we review important advances regarding the pathogenesis of membranous nephropathy. We will also review the current approach to treatment and its limitations and will highlight new therapies that are currently being explored for this disease including Ri...
متن کاملEarly versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial.
BACKGROUND Immunosuppressive therapy in idiopathic membranous nephropathy (iMN) is debated. Accurate identification of patients at high risk for end-stage renal disease (ESRD) allows early start of therapy in these patients. It is unknown if early start of therapy is more effective and/or less toxic than late start (i.e. when GFR deteriorates). METHODS We conducted a randomized open-label stu...
متن کاملChapter 7: Idiopathic membranous nephropathy
BACKGROUND The diagnosis of MN is made on kidney biopsy. Diagnostic features include capillary wall thickening, normal cellularity, IgG and C3 along capillary walls on immunofluorescence, and subepithelial deposits on electron microscopy. MN is often seen in association with an underlying disorder (secondary MN). Secondary MN is more common in children (75%) than adults (25%) (Table 12). The di...
متن کاملTreatment with rituximab in idiopathic membranous nephropathy
BACKGROUND Rituximab represents a valid therapeutic option to induce remission in patients with primary glomerulonephritis. Despite several studies proving its efficacy in improving outcomes in patients with membranous nephropathy (MN), its role in therapeutic protocols is not yet defined. METHODS We studied 38 patients with idiopathic MN treated with rituximab (in 13 patients as first-line t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Kidney International
سال: 1974
ISSN: 0085-2538
DOI: 10.1038/ki.1974.129